|
1
|
Brizel DM, Albers ME, Fisher SR, Scher RL,
Richtsmeier WJ, Hars V, George SL, Huang AT and Prosnitz LR:
Hyperfractionated irradiation with or without concurrent
chemotherapy for locally advanced head and neck cancer. N Engl J
Med. 338:1798–1804. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forastiere AA, Goepfert H, Maor M, Pajak
TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et
al: Concurrent chemotherapy and radiotherapy for organ preservation
in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Adelstein DJ, Li Y, Adams GL, Wagner H Jr,
Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup
phase III comparison of standard radiation therapy and two
schedules of concurrent chemoradiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Denis F, Garaud P, Bardet E, Alfonsi M,
Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J and Calais G:
Final results of the 94–01 French head and neck oncology and
radiotherapy group randomized trial comparing radiotherapy alone
with concomitant radiochemotherapy in advanced-stage oropharynx
carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Corvo R: Evidence-based radiation oncology
in head and neck squamous cell carcinoma. Radiother Oncol.
85:156–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernier J and Schneider D: Cetuximab
combined with radiotherapy: An alternative to chemoradiotherapy for
patients with locally advanced squamous cell carcinomas of the head
and neck? Eur J Cancer. 43:35–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spreafico A, Huang SH, Xu W, Granata R,
Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, et al:
Impact of cisplatin dose intensity on human papillomavirus-related
and -unrelated locally advanced head and neck squamous cell
carcinoma. Eur J Cancer. 67:174–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Szturz P, Wouters K, Kiyota N, Tahara M,
Prabhash K, Noronha V, Adelstein D, Van Gestel D and Vermorken JB:
Low-Dose vs. High-dose cisplatin: Lessons learned from 59
chemoradiotherapy trials in head and neck cancer. Front Oncol.
9:862019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Curran D, Giralt J, Harari PM, Ang KK,
Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, et
al: Quality of life in head and neck cancer patients after
treatment with high-dose radiotherapy alone or in combination with
cetuximab. J Clin Oncol. 25:2191–2197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu L: Pharmacokinetics of monoclonal
antibodies and Fc-fusion proteins. Protein Cell. 9:15–32. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dirks NL, Nolting A, Kovar A and Meibohm
B: Population pharmacokinetics of cetuximab in patients with
squamous cell carcinoma of the head and neck. J Clin Pharmacol.
48:267–278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aldoss IT, Plumb T, Zhen WK, Lydiatt DD
and Ganti AK: Cetuximab in hemodialysis: A case report. Head Neck.
31:1647–1650. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krens LL, Baas JM, Verboom MC, Paintaud G,
Desvignes C, Guchelaar HJ and Gelderblom H: Pharmacokinetics and
safety of cetuximab in a patient with renal dysfunction. Cancer
Chemother Pharmacol. 73:1303–1306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Forastiere AA, Zhang Q, Weber RS, Maor MH,
Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et
al: Long-term results of RTOG 91–11: A comparison of three
nonsurgical treatment strategies to preserve the larynx in patients
with locally advanced larynx cancer. J Clin Oncol. 31:845–852.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bourhis J, Sire C, Graff P, Grégoire V,
Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, et al:
Concomitant chemoradiotherapy versus acceleration of radiotherapy
with or without concomitant chemotherapy in locally advanced head
and neck carcinoma (GORTEC 99–02): An open-label phase 3 randomised
trial. Lancet Oncol. 13:145–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang SM and Harari PM: Modulation of
radiation response after epidermal growth factor receptor blockade
in squamous cell carcinomas: Inhibition of damage repair, cell
cycle kinetics, and tumor angiogenesis. Clin Cancer Res.
6:2166–2174. 2000.PubMed/NCBI
|
|
19
|
Milas L, Mason K, Hunter N, Petersen S,
Yamakawa M, Ang K, Mendelsohn J and Fan Z: In vivo enhancement of
tumor radioresponse by C225 antiepidermal growth factor receptor
antibody. Clin Cancer Res. 6:701–708. 2000.PubMed/NCBI
|
|
20
|
Harari PM and Huang SM: Head and neck
cancer as a clinical model for molecular targeting of therapy:
Combining EGFR blockade with radiation. Int J Radiat Oncol Biol
Phys. 49:427–433. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koutcher L, Sherman E, Fury M, Wolden S,
Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, et al:
Concurrent cisplatin and radiation versus cetuximab and radiation
for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol
Phys. 81:915–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Magrini SM, Buglione M, Corvo R, Pirtoli
L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M,
Lastrucci L, et al: Cetuximab and radiotherapy versus cisplatin and
radiotherapy for locally advanced head and neck cancer: A
randomized phase II trial. J Clin Oncol. 34:427–435. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bauml JM, Vinnakota R, Anna Park YH, Bates
SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani
R, et al: Cisplatin versus cetuximab with definitive concurrent
radiotherapy for head and neck squamous cell carcinoma: An analysis
of Veterans Health Affairs data. Cancer. 125:406–415. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gillison ML, Trotti AM, Harris J, Eisbruch
A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM,
Burtness B, et al: Radiotherapy plus cetuximab or cisplatin in
human papillomavirus-positive oropharyngeal cancer (NRG Oncology
RTOG 1016): A randomised, multicentre, non-inferiority trial.
Lancet. 393:40–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mehanna H, Robinson M, Hartley A, Kong A,
Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, et
al: Radiotherapy plus cisplatin or cetuximab in low-risk human
papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An
open-label randomised controlled phase 3 trial. Lancet. 393:51–60.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrelli F, Coinu A, Riboldi V, Borgonovo
K, Ghilardi M, Cabiddu M, Lonati V, Sarti E and Barni S:
Concomitant platinum-based chemotherapy or cetuximab with
radiotherapy for locally advanced head and neck cancer: A
systematic review and meta-analysis of published studies. Oral
Oncol. 50:1041–1048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang C, Chan C, Jiang W, Murphy JD, von
Eyben R, Colevas AD, Pinto H, Lee-Enriquez N, Kong C and Le QT:
Concurrent cetuximab versus platinum-based chemoradiation for the
definitive treatment of locoregionally advanced head and neck
cancer. Head Neck. 37:386–392. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Riaz N, Sherman E, Koutcher L, Shapiro L,
Katabi N, Zhang Z, Shi W, Fury M, Wong R, Wolden S, et al:
Concurrent chemoradiotherapy with cisplatin versus cetuximab for
squamous cell carcinoma of the head and neck. Am J Clin Oncol.
39:27–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiang M, Holsinger FC, Colevas AD, Chen
MM, Le QT and Beadle BM: Survival of patients with head and neck
cancer treated with definitive radiotherapy and concurrent
cisplatin or concurrent cetuximab: A Surveillance, Epidemiology,
and End Results-Medicare analysis. Cancer. 124:4486–4494. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Frampton JE: Spotlight on cetuximab in
squamous cell carcinoma of the head and necky. BioDrugs.
25:129–133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Villavicencio M, Granados-García M,
Vilajosana E and Domínguez-Cherit J: Management of radiodermatitis
associated with cetuximab in squamous cell carcinomas of the head
and neck. Int J Dermatol. 56:602–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lugtenberg RT, Boers-Doets CB, Witteveen
PO, van Herpen CML, Wymenga ANM, de Groot JWB, Hoeben A, Del Grande
C, van Doorn B, Koldenhof JJ, et al: Prospective practice survey of
management of cetuximab-related skin reactions. Support Care
Cancer. 29:3497–3506. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bonomo P, Loi M, Desideri I, Olmetto E,
Delli Paoli C, Terziani F, Greto D, Mangoni M, Scoccianti S,
Simontacchi G, et al: Incidence of skin toxicity in squamous cell
carcinoma of the head and neck treated with radiotherapy and
cetuximab: A systematic review. Crit Rev Oncol Hematol. 120:98–110.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mayfield JD, Mercado CE, Kaye FJ and
Mendenhall WM: Cetuximab-associated pulmonary toxicity in
concurrent chemoradiation for the treatment of a squamous cell
carcinoma of the head and neck. Head Neck. 41:E55–E58. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Machiels JP, Rene Leemans C, Golusinski W,
Grau C, Licitra L and Gregoire V; EHNS Executive Board. Electronic
address, : simplesecretariat@ehns.org;
ESMO Guidelines Committee. Electronic address: simpleclinicalguidelines@esmo.org;
ESTRO Executive Board. Electronic address: simpleinfo@estro.org: Squamous
cell carcinoma of the oral cavity, larynx, oropharynx and
hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 31:1462–1475. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kintzel PE and Dorr RT: Anticancer drug
renal toxicity and elimination: Dosing guidelines for altered renal
function. Cancer Treat Rev. 21:33–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Torres da Costa E Silva V, Costalonga EC,
Coelho FO, Caires RA and Burdmann EA: Assessment of kidney function
in patients with cancer. Adv Chronic Kidney Dis. 25:49–56. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ragin CC and Taioli E: Survival of
squamous cell carcinoma of the head and neck in relation to human
papillomavirus infection: Review and meta-analysis. Int J Cancer.
121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pignon JP, le Maitre A, Maillard E and
Bourhis J; MACH-NC Collaborative Group, : Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sanabria A, Carvalho AL, Vartanian JG,
Magrin J, Ikeda MK and Kowalski LP: Comorbidity is a prognostic
factor in elderly patients with head and neck cancer. Ann Surg
Oncol. 14:1449–1457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Homma A, Hayashi R, Kawabata K, Fujii T,
Iwae S, Hasegawa Y, Nibu K, Kato T, Shiga K, Matsuura K, et al:
Association of impaired renal function and poor prognosis in
oropharyngeal squamous cell carcinoma. Head Neck. 38:1495–1500.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kiyota N, Tahara M, Fujii H, Yamazaki T,
Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, et al:
Phase II/III trial of post-operative chemoradiotherapy comparing
3-weekly cisplatin with weekly cisplatin in high-risk patients with
squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol.
38 (15_suppl):S65022020. View Article : Google Scholar
|
